Alpha-1 antitrypsin deficiency: AU general practice guide

What alpha-1 antitrypsin deficiency is

Alpha-1 antitrypsin (AAT) is a protein produced by the liver that circulates in the bloodstream and shields the lungs from inflammatory enzymes — particularly neutrophil elastase — that would otherwise break down alveolar tissue. When the SERPINA1 gene on chromosome 14 carries pathological variants, most importantly the Z allele, the liver either secretes far too little AAT or produces a misfolded version that cannot leave hepatocytes.

Alpha-1 antitrypsin deficiency (AATD) is inherited in an autosomal codominant pattern — both copies of SERPINA1 contribute to the circulating protein level. The classification system uses Pi (protease inhibitor) nomenclature based on electrophoretic mobility. The normal genotype is PiMM. The most clinically significant severe genotype is PiZZ, affecting roughly 1 in 3,000–5,000 Australians — an estimated 5,000–10,000 people — of whom fewer than 10% are ever diagnosed during their lifetime.

The defining clinical problem is diagnostic delay. According to data from the Alpha-1 Foundation and replicated in Stoller and Aboussouan AJRCCM 2012, the average time from first respiratory symptoms to diagnosis is 5–10 years. General practitioners in Australia managing adults with COPD, asthma with persistent obstruction, or cryptogenic liver disease are almost certainly looking after undiagnosed AATD patients.

A. Core clinical — the AU general practice framework

Who to screen

Per the ATS/ERS standards for AATD diagnosis and management — endorsed by GOLD 2024 and incorporated into the COPD-X Plan v2.78 (October 2025) — the following groups should have a one-time serum AAT level:

• All adults with COPD, regardless of age, smoking history, or severity
• Adults with asthma and persistent post-bronchodilator airflow obstruction
• Adult bronchiectasis without a clearly identified cause
• Cryptogenic cirrhosis or hepatitis at any age
• First-degree relatives of a confirmed AATD patient
• Adults with granulomatosis with polyangiitis (GPA / Wegener’s) or other ANCA-associated vasculitis
• Neonates with cholestasis persisting beyond two weeks with conjugated hyperbilirubinaemia
• Adults with unexplained panniculitis

Pi phenotypes

The clinically important Pi types for general practice are:

• PiMM — wild type; serum AAT level 20–53 µmol/L; no disease risk
• PiMZ — heterozygous carrier; approximately 3% of Australians (~750,000 people); levels ~60–80% of normal; mild risk only in the presence of cofactors such as smoking, obesity, or alcohol
• PiSZ — compound heterozygote; moderate deficiency (~40% of normal); emphysema risk, especially with smoking
• PiZZ — homozygous Z; severe deficiency (~15% of normal); classical clinical phenotype; ~1 in 3,000–5,000 Australians
• PiNull — extremely rare; no protein produced; highest emphysema risk, but no liver disease (no protein to accumulate in hepatocytes)

Diagnostic workup

The workup follows a stepwise sequence recommended by Alpha-1 Foundation clinical guidance:

1. Serum AAT level (MBS item 66614) — first-line; a result below 11 µmol/L (~60 mg/dL) falls below the protective threshold and warrants further testing. Note that AAT is an acute-phase reactant — inflammation, active infection, pregnancy, and the oral contraceptive pill can falsely normalise a low level; request CRP simultaneously and interpret accordingly.

2. Phenotyping by isoelectric focusing (IEF) — confirms the Pi type; typically reflexed by the laboratory when the level is low.

3. SERPINA1 genotyping (MBS item 73289, verify current Medicare eligibility) — for atypical phenotypes, suspected dysfunctional variants, or PiNull confirmation; arranged through clinical genetics services or specialist pathology.

4. Pulmonary function testing — pre- and post-bronchodilator spirometry (MBS 11506) and diffusing capacity (DLCO, MBS 11512); an obstructive pattern with markedly reduced DLCO is characteristic of established emphysema.

5. HRCT chest (MBS 56507/56807) — basal-predominant panacinar emphysema is the distinguishing imaging feature; the opposite of the centrilobular upper-lobe pattern typical of smoking-related COPD.

6. Liver assessment — baseline LFT, INR, albumin, bilirubin, and AFP in all PiZZ patients; transient elastography (FibroScan) for fibrosis staging via hepatology referral.

Core management

Smoking cessation is the single most important intervention. The landmark Janus Lancet 1985 study demonstrated that PiZZ smokers lose approximately 100 mL of FEV1 per year — roughly three times the rate in non-smokers (~30 mL/year). No pharmacotherapy, including augmentation therapy, achieves comparable benefit. Combination NRT or varenicline (PBS Authority Streamlined) is first-line; refer to Quitline 13 78 48.

Standard COPD management per COPD-X v2.78 applies in full — stepwise bronchodilator therapy, a written COPD action plan with at-home antibiotic and prednisolone protocols, and pulmonary rehabilitation. Cochrane evidence (McCarthy 2015) shows pulmonary rehabilitation reduces hospitalisations by 39% with a mortality benefit on adherence.

Vaccinations are important at a higher standard than general COPD care, because AATD patients carry both chronic lung and chronic liver vulnerability. Per the Australian Immunisation Handbook: annual influenza (NIP-funded for chronic respiratory disease), Prevenar 20 (NIP, single dose for chronic lung disease), COVID-19 boosters per ATAGI, hepatitis A and B (NIP-funded under chronic liver disease indication), and RSV vaccination for adults ≥75 or those aged 60–74 with high-risk features.

B. Pulmonary and hepatic complications

Lung disease — loss-of-function mechanism

The pulmonary mechanism is loss-of-function: insufficient circulating AAT leaves neutrophil elastase unopposed in the alveolar wall, gradually destroying the elastin scaffold. The resulting emphysema is panacinar in pattern and basal-predominant — the opposite of the centrilobular upper-lobe distribution typical of smoking COPD. Seeing basal-predominant emphysema on imaging is a clear trigger to check AAT level, even in a current smoker.

Emphysema typically becomes symptomatic before age 45 in PiZZ non-smokers and before age 30 in PiZZ smokers per ATS/ERS guidance. Bronchiectasis complicates the course in approximately 30% of patients, presenting with chronic productive cough and recurrent lower respiratory infections. Adult-onset asthma with persistent post-bronchodilator obstruction is a further presentation that should prompt AAT testing.

Liver disease — gain-of-function mechanism

Liver disease is independent of lung disease and caused by a separate mechanism: Z-variant AAT protein is misfolded and cannot be secreted normally from hepatocytes. It polymerises inside the endoplasmic reticulum, forming PAS-positive diastase-resistant inclusions that are gradually toxic. A patient can have severe lung disease, severe liver disease, both, or neither, depending on genotype and cofactors.

Neonatal cholestasis (prolonged jaundice with conjugated hyperbilirubinaemia beyond two weeks) occurs in approximately 10% of PiZZ infants. About 30% of PiZZ adults develop cirrhosis by age 50, with risk higher in those with concurrent obesity, alcohol use, or viral hepatitis co-infection. Hepatocellular carcinoma risk is approximately five times higher in cirrhotic PiZZ patients compared with the general population — making six-monthly hepatic ultrasound and AFP the standard of care per GESA hepatology guidance.

PiNull patients produce no protein at all and have no liver disease (nothing to accumulate), but suffer the most severe emphysema because neutrophil elastase operates entirely without inhibition.

Rare manifestations

Panniculitis — tender erythematous nodules and ulceration — occurs rarely in severe AATD and is one of the accepted indications for augmentation therapy. An association between AATD and ANCA-associated vasculitis (particularly GPA with c-ANCA/PR3 positivity) is under-recognised; ATS/ERS 2003 lists it as a screening indication.

C. Augmentation therapy and access in Australia

Evidence base

Augmentation therapy delivers pooled human plasma-derived AAT by weekly intravenous infusion, typically at 60 mg/kg, to raise circulating levels above the protective threshold. The pivotal RAPID trial (Chapman, Lancet 2015) was a randomised controlled trial showing that augmentation slowed CT-densitometry-measured emphysema progression versus placebo. The Edgar Cochrane review 2017 confirmed a modest slowing of emphysema progression; no clear mortality benefit has been demonstrated and the effect on FEV1 trajectory is small. The clinical benefit is real but modest.

Indications per ATS/ERS 2003 are confirmed severe deficiency (PiZZ, selected PiSZ or PiNull), established emphysema (FEV1 typically 30–65% predicted), and ex-smoker or never-smoker status — smoking negates any benefit and dramatically accelerates progression.

Australian access pathway

The available products — Prolastin-C (Grifols), Glassia (Kamada), and Aralast NP (Takeda) — are not TGA-registered in Australia. Access requires an individual TGA Special Access Scheme (SAS) Category B application prepared by the treating specialist. Cost is approximately $60,000–$100,000 per year, entirely self-funded — not listed on the PBS and not reimbursed by private health insurance. This is a major equity barrier that GPs should counsel patients about explicitly and early.

The Alpha-1 Foundation provides patient advocacy, registry enrolment (which may facilitate access at no cost through research pathways), and updated SAS application guidance. The Lung Foundation Australia is engaged in advocacy for TGA registration and PBS listing.

D. Australian operations

Key MBS items

• 23/36/44 — Level B/C/D GP consultation
• 91790/92029/92060 — Telehealth video/phone equivalents (12-month existing-relationship rule)
• 66614 — Serum AAT level and phenotype
• 73289 — SERPINA1 genotyping (verify current Medicare eligibility before ordering)
• 11506/11512 — Pre/post-bronchodilator spirometry and DLCO
• 56507/56807 — HRCT chest
• 55036/55054 — Hepatic ultrasound and Doppler for HCC surveillance
• 65070 — Pathology bundle (FBC, UEC, LFT, INR, AFP)
• 132/133 — Respiratory physician or hepatologist consultation (initial/subsequent management plan)
• 105/106 — Specialist referral attendances (clinical genetics, lung or liver transplant)
• 965/967 — GP Chronic Condition Management Plan (post July 2025) — AATD with COPD or cirrhotic comorbidity qualifies
• 2715/2717 — Mental Health Care Plan — warranted for chronic disease burden, genetic disclosure distress, or transplant trajectory

PBS items

Smoking cessation pharmacotherapy (varenicline, bupropion, NRT) is PBS Authority Streamlined. COPD inhalers — SABA, SAMA, LAMA, LABA combinations, and triple ICS/LAMA/LABA — are Authority Required (Streamlined) for COPD. NIP vaccines as above are funded. Augmentation therapy is not PBS-listed — TGA SAS only, entirely self-funded.

Cascade family testing and genetic counselling

All confirmed AATD patients should be offered referral to facilitate cascade testing of first-degree relatives. Pre-test counselling covers life-insurance implications (the Life Insurance Code of Practice moratorium currently protects up to $500,000 cover from genetic-result discrimination — review this at the time of testing), employment considerations, and reproductive planning. Clinical genetics services coordinate cascade testing. The process is cost-effective per Lieberman Am J Med 2007 data and catches affected individuals before symptoms develop.

Referral pathways

Respiratory physician for all confirmed AATD with lung disease and for augmentation therapy candidacy assessment. Hepatologist for all PiZZ adults at baseline and for established hepatic dysfunction. Liver transplant units for decompensated cirrhosis or HCC within Milan criteria (Austin VIC, RPA and Liverpool NSW, PAH QLD, SCGH WA). Lung transplant units for FEV1 below 30% with refractory disease (Alfred VIC, St Vincent’s NSW, Prince Charles QLD). Clinical genetics for cascade testing coordination and reproductive counselling.

What to include in a referral: spirometry and DLCO trends, HRCT report, full LFT with INR, AFP, and FibroScan result, AAT level with phenotype and genotype, family pedigree, full smoking history with pack-year estimate, vaccination records, and occupational exposure history.

E. Special populations

Neonates and children. Prolonged neonatal cholestasis (conjugated jaundice persisting beyond two weeks) places AATD in the differential — refer to paediatric hepatology. Most affected infants resolve without intervention, but approximately 25% progress to childhood cirrhosis. Paediatric lung disease is rare; emphysema typically does not manifest until adulthood.

PiMZ carriers. Most have near-normal lung and liver function throughout life provided they avoid smoking, maintain alcohol within low-risk limits per NHMRC guidelines, and address any coexisting fatty liver disease. They do not require augmentation therapy monitoring. Reproductive counselling is warranted if their partner may carry a Z allele — a PiMZ × PiMZ couple has a 1 in 4 chance of a PiZZ child.

ATSI patients. PiZZ frequency is lower in non-European-ancestry populations but AATD is not exclusively a condition of Northern European ancestry. The 715 Aboriginal and Torres Strait Islander Health Assessment (MBS 715) provides an opportunity to identify at-risk individuals with respiratory or hepatic disease. The Closing the Gap PBS co-payment for smoking cessation pharmacotherapy and Aboriginal Health Worker support are important adjuncts.

Older adults. Standard management principles apply. Falls risk from hypoxaemia, deconditioning, and polypharmacy warrants regular review. Long-term oxygen therapy follows standard COPD criteria (PaO2 ≤55 mmHg). Advance care planning — aligned with the Chronic Condition Management Plan — is appropriate early in the disease trajectory.

Pregnancy. AATD itself does not contraindicate pregnancy. Augmentation therapy in pregnancy is not established; manage in collaboration with respiratory and obstetric teams in severe cases.

Occupational exposure. Mineral dust and fume inhalation accelerates lung decline in AATD beyond the effect seen in the general population. An occupational history is mandatory at every review. Work-related exposure triggering significant respiratory decline warrants SafeWork notification under state dust-disease or occupational respiratory disease schemes.

When to escalate

Escalate urgently (same day or emergency department) for:

• Acute COPD exacerbation with respiratory failure or hypercapnia
• Haematemesis or signs of variceal bleeding in a cirrhotic patient

Escalate same week for:

• Newly confirmed PiZZ or PiNull with any respiratory or hepatic symptoms — respiratory physician and hepatology rapid access
• New cirrhosis diagnosis
• New HCC on surveillance imaging

Routine specialist referral for:

• All confirmed AATD for baseline respiratory and hepatic assessment
• Augmentation therapy candidacy evaluation
• Lung or liver transplant consideration (FEV1 below 30%, decompensated cirrhosis)
• Cascade family testing and genetic counselling coordination

What this article is and is not

This is general health information for patients and carers, drawn from current Australian clinical guidance — the COPD-X Plan v2.78 (Lung Foundation Australia / TSANZ), Therapeutic Guidelines (eTG), ATS/ERS AATD standards, GOLD 2024, GESA hepatology guidance, and RACGP genetics resources. It does not constitute personal medical advice and does not create a doctor–patient relationship. Decisions about testing, treatment, and referral are made with your own GP and specialist team.

For consumer-level information: HealthDirect — Alpha-1 antitrypsin deficiency, Lung Foundation Australia, Alpha-1 Foundation, Better Health Channel.

For patient support and advocacy: the Alpha-1 Foundation maintains patient registries and connects patients with augmentation therapy access support and clinical trial enrolment opportunities.

---

Sources cited

1. Alpha-1 Foundation — clinical guidance
2. ATS/ERS — Standards for the Diagnosis and Management of Alpha-1 Antitrypsin Deficiency (AJRCCM 2003)
3. Australian Immunisation Handbook
4. Better Health Channel
5. Chapman KR et al. — RAPID trial, augmentation therapy (Lancet 2015)
6. Edgar RG et al. — Cochrane review of augmentation therapy 2017
7. eTG complete — Alpha-1 antitrypsin deficiency
8. GESA — Hepatology guidance
9. GOLD 2024 — Global Strategy for Diagnosis, Management and Prevention of COPD
10. HealthDirect — Alpha-1 antitrypsin deficiency
11. Janus ED et al. — Smoking and FEV1 decline in PiZZ AATD (Lancet 1985)
12. Lung Foundation Australia / TSANZ — COPD-X Plan v2.78 October 2025
13. McCarthy B et al. — Pulmonary rehabilitation (Cochrane 2015)
14. MBS Online
15. NHMRC — Australian Alcohol Guidelines
16. PBS
17. RACGP — Genetics in general practice
18. Stoller JK, Aboussouan LS — Review of alpha-1-AT deficiency (AJRCCM 2012)
19. TGA Special Access Scheme — Prolastin / Glassia / Aralast NP